Alinidine
Systematic (IUPAC) name | |
---|---|
N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine | |
Clinical data | |
| |
Identifiers | |
33178-86-8 | |
None | |
PubChem | CID 36354 |
ChemSpider | 33429 |
UNII | E7IDJ8DS1D |
ChEMBL | CHEMBL278581 |
Chemical data | |
Formula | C12H13Cl2N3 |
270.16 g/mol | |
SMILES
| |
| |
(what is this?) (verify) |
Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.[2]
Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.[3]
References
- ↑ Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflugers Arch 1987, 410:83-91
- ↑ Current Opinion in Pharmacology 2007, 7:208–213
- ↑ Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.". J Am Coll Cardiol 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.
|
|